Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fundación de investigación HM
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Centre Oscar Lambret
M.D. Anderson Cancer Center
Endeavor Biomedicines, Inc.
M.D. Anderson Cancer Center
Eli Lilly and Company
Servier
Jazz Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Research UK
Turning Point Therapeutics, Inc.
City of Hope Medical Center
Stanford University
Milton S. Hershey Medical Center
Novartis
University of Alabama at Birmingham
Mayo Clinic
Eli Lilly and Company
University of Nebraska
Thomas Jefferson University
Institut du Cancer de Montpellier - Val d'Aurelle
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Blueprint Medicines Corporation
Northwell Health
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Lumos Pharma
Washington University School of Medicine
University of Alabama at Birmingham
Deciphera Pharmaceuticals, LLC
Eisai Inc.